KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.
User applied Hims topical finasteride/minoxidil cocktail nightly, with weekly oil massages and ketoconazole shampoo. They also use vitamin D and biotin occasionally.
Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.
Estrogen injections significantly improved hair growth, particularly on the crown, after stopping finasteride. Monotherapy with estrogen led to hairline improvement, but also caused sterility and potential feminization effects.
The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.
The user reported progress in hair growth after 1.5 months on oral minoxidil, 1 month on oral finasteride, and microneedling every other week. They thanked the community for support and decided to continue treatment while stepping away from the forum.
The conversation is about using oral finasteride and minoxidil for hair loss, with consideration of adding topical GHK-Cu for skin and hair benefits. The user seeks opinions on this combination.
The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.
The user is using Minoxidil, RU58841, CB-03-01, WAY-316606, Ketoconazole, MK-677, and derma stamping to treat hair loss and has noticed new hair growth, especially around the temples and hairline. They apply different treatments at various times of the day and have seen improvements in skin condition and body hair texture.
The conversation is about a user's one-year progress after a 3,200 graft FUE hair transplant and their use of oral finasteride and minoxidil. People are impressed with the results and are discussing the effectiveness and cost of the treatment.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
Mixing Nizoral and T-Gel in a 1:1 ratio and using it three times a week provided relief from persistent seborrheic dermatitis. This treatment is recommended for those with stubborn SD.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
The user shared progress pictures showing hair improvement from using oral finasteride and topical minoxidil between September 2023 and May 2026. Responses express amazement at the results.
A user is concerned about the legitimacy of a hair growth serum called Lavdik, which they ordered after seeing an ad for Jemros. The product contains ginger extract, ginseng extract, fleece flower root, grape seed oil, glycerol, carbomer, propylene glycol, and rosemary oil, and the user is unsure if it is effective or a scam.
The conversation is about finding an online pharmacy within the EU that sells oral minoxidil and finasteride. Recommendations include Justhair and Minoxidiexpress.
The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
A user shaved their transplanted hair during quarantine and shared positive results after one year, using Minoxidil 5%. They had 1,500 hairs transplanted via the DHI method with no visible scarring.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.